Although almost 70% of patients with NSCLC present with locally advanced or metastatic disease at the time of diagnosis [16,17], KRAS and EGFR mutation status is most commonly assessed only in the primary tumor tissue based on the assumption that primary and metastases are pathologically concordant. This evidence concerns the gene KRAS and non-small cell lung carcinoma.